BioCryst Pharmaceuticals | BCRX - 流动负债

股票价格
8.30
每天变化
-0.73 -8.08%
每月一次
-13.45%
每年
-17.66%
Q2 预测
9.00


金融业
股票价格
USD
资产
USD 514.16M
现金及等价物
USD 335.91M
销售成本
USD 9.52M
流动资产
USD 404.35M
流动负债
USD 196.07M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -119.15M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 428.67M
市值
USD 1.71B
净收入
USD 245.85M
营业费用
USD 146.17M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.4M
贸易债权人
USD 15.83M
应收帐款人
USD 106.82M


流动负债 更改 日
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
BioCryst Pharmaceuticals USD 196.07M 5.83M 2025-12
Chugai Pharma JPY 327.7B 83.38B 2026-03
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
DBV Technologies USD 58.02M 8.54M 2025-12
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Incyte USD 1.49B 25.52M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novavax USD 342.46M 117.49M 2026-03
PTC Therapeutics USD 968.43M 102.18M 2025-12
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03